Trial Profile
A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Duvelisib (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2023 Planned End Date changed from 1 Jul 2030 to 1 Jul 2025.
- 01 Apr 2021 Primary endpoint (Number of Patients Who Had a Minimal Residual Disease (MRD) Negative Complete Response (CR) 2 Months After Chemotherapy) has not been met, according to the results published in the Leukemia.
- 01 Apr 2021 Results assessing the efficacy and safety of duvelisib + FCR (DFCR) as initial therapy for younger CLL patients, published in the Leukemia.